Soligenix, Inc.

Healthcare · Biotechnology · United States

Last price 0.3559 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 7.75M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment ...